Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, I. C.
Right arrow Articles by Sharp, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, I. C.
Right arrow Articles by Sharp, P. F.
Journal of Clinical Oncology, Vol 18, Issue 8 (April), 2000: 1676-1688
© 2000 American Society for Clinical Oncology

Positron Emission Tomography Using [18F]-Fluorodeoxy-D-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy

By Ian C. Smith, Andrew E. Welch, Andrew W. Hutcheon, Iain D. Miller, Simon Payne, Felice Chilcott, Smruti Waikar, Teena Whitaker, Antoinne K. Ah-See, Oleg Eremin, Steven D. Heys, Fiona J. Gilbert, Peter F. Sharp

From the John Mallard Scottish Positron Emission Tomography Center; Departments of Bio-Medical PhysicsSurgery, and Radiology, University of Aberdeen; and Departments of Oncology and Pathology, Grampian University Hospitals National Health Service Trust, Aberdeen, Scotland, United Kingdom.

Address reprint requests to Ian Smith, MB, ChB, Department of Academic Radiology, University of Aberdeen, Foresterhill House Annex, Foresterhill, Aberdeen, AB25 2ZD Scotland, United Kingdom; email i.c.smith{at}abdn.ac.uk

PURPOSE: To determine whether [18F]-fluorodeoxy-D-glucose ([18F]-FDG) positron emission tomography (PET) can predict the pathologic response of primary and metastatic breast cancer to chemotherapy.

PATIENTS AND METHODS: Thirty patients with noninflammatory, large (> 3 cm), or locally advanced breast cancers received eight doses of primary chemotherapy. Dynamic PET imaging was performed immediately before the first, second, and fifth doses and after the last dose of treatment. Primary tumors and involved axillary lymph nodes were identified, and the [18F]-FDG uptake values were calculated (expressed as semiquantitative dose uptake ratio [DUR] and influx constant [K]). Pathologic response was determined after chemotherapy by evaluation of surgical resection specimens.

RESULTS: Thirty-one primary breast lesions were identified. The mean pretreatment DUR values of the eight lesions that achieved a complete microscopic pathologic response were significantly (P = .037) higher than those from less responsive lesions. The mean reduction in DUR after the first pulse of chemotherapy was significantly greater in lesions that achieved a partial (P = .013), complete macroscopic (P = .003), or complete microscopic (P = .001) pathologic response. PET after a single pulse of chemotherapy was able to predict complete pathologic response with a sensitivity of 90% and a specificity of 74%. Eleven patients had pathologic evidence of lymph node metastases. Mean pretreatment DUR values in the metastatic lesions that responded did not differ significantly from those that failed to respond (P = .076). However, mean pretreatment K values were significantly higher in ultimately responsive cancers (P = .037). The mean change in DUR and K after the first pulse of chemotherapy was significantly greater in responding lesions (DUR, P = .038; K, P = .012).

CONCLUSION: [18F]-FDG PET imaging of primary and metastatic breast cancer after a single pulse of chemotherapy may be of value in the prediction of pathologic treatment response.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M.-L. W. Ah-See, A. Makris, N. J. Taylor, M. Harrison, P. I. Richman, R. J. Burcombe, J. J. Stirling, J. A. d'Arcy, D. J. Collins, M. R. Pittam, et al.
Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Clin. Cancer Res., October 15, 2008; 14(20): 6580 - 6589.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. K. Dunnwald, J. R. Gralow, G. K. Ellis, R. B. Livingston, H. M. Linden, J. M. Specht, R. K. Doot, T. J. Lawton, W. E. Barlow, B. F. Kurland, et al.
Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer
J. Clin. Oncol., September 20, 2008; 26(27): 4449 - 4457.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Bergstrom, A. Monazzam, P. Razifar, S. Ide, R. Josephsson, and B. Langstrom
Modeling Spheroid Growth, PET Tracer Uptake, and Treatment Effects of the Hsp90 Inhibitor NVP-AUY922
J. Nucl. Med., July 1, 2008; 49(7): 1204 - 1210.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
U. Tateishi, C. Gamez, S. Dawood, H. W. D. Yeung, M. Cristofanilli, and H. A. Macapinlac
Bone Metastases in Patients with Metastatic Breast Cancer: Morphologic and Metabolic Monitoring of Response to Systemic Therapy with Integrated PET/CT
Radiology, April 1, 2008; 247(1): 189 - 196.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. C. Hodgson and K. Y. Gulenchyn
Is There a Role for Positron Emission Tomography in Breast Cancer Staging?
J. Clin. Oncol., February 10, 2008; 26(5): 712 - 720.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. C. Wolff, D. Berry, L. A. Carey, M. Colleoni, M. Dowsett, M. Ellis, J. E. Garber, D. Mankoff, S. Paik, L. Pusztai, et al.
Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer
J. Clin. Oncol., February 10, 2008; 26(5): 806 - 813.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. K. Schwarz, B. A. Siegel, F. Dehdashti, and P. W. Grigsby
Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma
JAMA, November 21, 2007; 298(19): 2289 - 2295.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
E. L. Rosen, W. B. Eubank, and D. A. Mankoff
FDG PET, PET/CT, and Breast Cancer Imaging
RadioGraphics, October 1, 2007; 27(suppl_1): S215 - S229.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
C. K. Kuhl
Current Status of Breast MR Imaging * Part 2. Clinical Applications
Radiology, September 1, 2007; 244(3): 672 - 691.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. J. Francis, M. J. Byrne, A. A. van der Schaaf, J. A. Boucek, A. K. Nowak, M. Phillips, R. Price, A. P. Patrikeos, A. W. Musk, and M. J. Millward
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
J. Nucl. Med., September 1, 2007; 48(9): 1449 - 1458.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn
Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond
Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Nahmias, W. T. Hanna, L. M. Wahl, M. J. Long, K. F. Hubner, and D. W. Townsend
Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients with 18F-FDG PET/CT
J. Nucl. Med., May 1, 2007; 48(5): 744 - 751.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
C. Shimizu, M. Ando, T. Kouno, N. Katsumata, and Y. Fujiwara
Current Trends and Controversies over Pre-operative Chemotherapy for Women with Operable Breast Cancer
Jpn. J. Clin. Oncol., January 3, 2007; (2007) hyl122v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
L. Tafra
Positron Emission Tomography (PET) and Mammography (PEM) for Breast Cancer: Importance to Surgeons
Ann. Surg. Oncol., January 1, 2007; 14(1): 3 - 13.
[Full Text] [PDF]

Home page
 JCOHome page
C. Rousseau, A. Devillers, C. Sagan, L. Ferrer, B. Bridji, L. Campion, M. Ricaud, E. Bourbouloux, I. Doutriaux, M. Clouet, et al.
Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography
J. Clin. Oncol., December 1, 2006; 24(34): 5366 - 5372.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Couturier, G. Jerusalem, J.-M. N'Guyen, and R. Hustinx
Sequential Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Response to Chemotherapy in Metastatic Breast Cancer.
Clin. Cancer Res., November 1, 2006; 12(21): 6437 - 6443.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. M. Linden, K. A. Krohn, R. B. Livingston, and D. A. Mankoff
Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
Clin. Cancer Res., October 1, 2006; 12(19): 5608 - 5610.
[Full Text] [PDF]

Home page
 Ann OncolHome page
S. Semple, R. Staff, S. Heys, T. Redpath, A. Welch, T. Ahearn, A. Hutcheon, and F. Gilbert
Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration
Ann. Onc., September 1, 2006; 17(9): 1393 - 1398.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K.-H. Lee, S.-H. Lee, D.-W. Kim, W. J. Kang, J.-K. Chung, S.-A. Im, T.-Y. Kim, Y. W. Kim, Y.-J. Bang, and D. S. Heo
High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.
Clin. Cancer Res., July 15, 2006; 12(14): 4232 - 4236.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Cachin, H. M. Prince, A. Hogg, R. E. Ware, and R. J. Hicks
Powerful Prognostic Stratification By [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy
J. Clin. Oncol., July 1, 2006; 24(19): 3026 - 3031.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum
Primary Systemic Therapy of Breast Cancer
Oncologist, June 1, 2006; 11(6): 574 - 589.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. E. Juweid and B. D. Cheson
Positron-Emission Tomography and Assessment of Cancer Therapy
N. Engl. J. Med., February 2, 2006; 354(5): 496 - 507.
[Full Text] [PDF]

Home page
 JCOHome page
D. S. Hawkins, S. M. Schuetze, J. E. Butrynski, J. G. Rajendran, C. B. Vernon, E. U. Conrad III, and J. F. Eary
[18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors
J. Clin. Oncol., December 1, 2005; 23(34): 8828 - 8834.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. W. Moon, S. Y. Rha, H. C. Jeung, W. I. Yang, C. O. Suh, and H. C. Chung
Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis
Ann. Onc., November 1, 2005; 16(11): 1778 - 1785.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
W A Weber
PET for response assessment in oncology: radiotherapy and chemotherapy
Br. J. Radiol., November 1, 2005; Supplement_28(1): 42 - 49.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Avril, S. Sassen, B. Schmalfeldt, J. Naehrig, S. Rutke, W. A. Weber, M. Werner, H. Graeff, M. Schwaiger, and W. Kuhn
Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced-Stage Ovarian Cancer
J. Clin. Oncol., October 20, 2005; 23(30): 7445 - 7453.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Dose Schwarz, M. Bader, L. Jenicke, G. Hemminger, F. Janicke, and N. Avril
Early Prediction of Response to Chemotherapy in Metastatic Breast Cancer Using Sequential 18F-FDG PET
J. Nucl. Med., July 1, 2005; 46(7): 1144 - 1150.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. A. Weber
Use of PET for Monitoring Cancer Therapy and for Predicting Outcome
J. Nucl. Med., June 1, 2005; 46(6): 983 - 995.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Quon and S. S. Gambhir
FDG-PET and Beyond: Molecular Breast Cancer Imaging
J. Clin. Oncol., March 10, 2005; 23(8): 1664 - 1673.
[Full Text] [PDF]

Home page
 JBJSHome page
E. U. Conrad III, H. D. Morgan, C. Vernon, S. M. Schuetze, and J. F. Eary
Fluorodeoxyglucose Positron Emission Tomography Scanning: Basic Principles and Imaging of Adult Soft-Tissue Sarcomas
J. Bone Joint Surg. Am., December 1, 2004; 86(suppl_2): 98 - 104.
[Full Text] [PDF]

Home page
 ChestHome page
F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski
Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer
Chest, November 1, 2004; 126(5): 1656 - 1666.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Tseng, L. K. Dunnwald, E. K. Schubert, J. M. Link, S. Minoshima, M. Muzi, and D. A. Mankoff
18F-FDG Kinetics in Locally Advanced Breast Cancer: Correlation with Tumor Blood Flow and Changes in Response to Neoadjuvant Chemotherapy
J. Nucl. Med., November 1, 2004; 45(11): 1829 - 1837.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S.-J. Kim, S.-k. Kim, E. S. Lee, J. Ro, and S. h. Kang
Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy
Ann. Onc., September 1, 2004; 15(9): 1352 - 1357.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J.M. van der Hoeven, N. C. Krak, O. S. Hoekstra, E. F.I. Comans, R. P.A. Boom, D. van Geldere, S. Meijer, E. van der Wall, J. Buter, H. M. Pinedo, et al.
18F-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging of Locally Advanced Breast Cancer
J. Clin. Oncol., April 1, 2004; 22(7): 1253 - 1259.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. A. Wieder, B. L.D.M. Brucher, F. Zimmermann, K. Becker, F. Lordick, A. Beer, M. Schwaiger, U. Fink, J. R. Siewert, H. J. Stein, et al.
Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment
J. Clin. Oncol., March 1, 2004; 22(5): 900 - 908.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Ott, U. Fink, K. Becker, A. Stahl, H.-J. Dittler, R. Busch, H. Stein, F. Lordick, T. Link, M. Schwaiger, et al.
Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective Trial
J. Clin. Oncol., December 15, 2003; 21(24): 4604 - 4610.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. A. Mankoff, L. K. Dunnwald, J. R. Gralow, G. K. Ellis, E. K. Schubert, J. Tseng, T. J. Lawton, H. M. Linden, and R. B. Livingston
Changes in Blood Flow and Metabolism in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy
J. Nucl. Med., November 1, 2003; 44(11): 1806 - 1814.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. J. Biersack and H. Palmedo
Locally Advanced Breast Cancer: Is PET Useful for Monitoring Primary Chemotherapy?
J. Nucl. Med., November 1, 2003; 44(11): 1815 - 1817.
[Full Text] [PDF]

Home page
 JCOHome page
W. A. Weber, V. Petersen, B. Schmidt, L. Tyndale-Hines, T. Link, C. Peschel, and M. Schwaiger
Positron Emission Tomography in Non-Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use
J. Clin. Oncol., July 15, 2003; 21(14): 2651 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith
Clinical Role of FDG PET in Evaluation of Cancer Patients
RadioGraphics, March 1, 2003; 23(2): 315 - 340.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Kostakoglu and S. J. Goldsmith
18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma
J. Nucl. Med., February 1, 2003; 44(2): 224 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
E. A. Levine, R. I. Freimanis, N. D. Perrier, K. Morton, N. M. Lesko, S. Bergman, K. R. Geisinger, R. C. Williams, C. Sharpe, V. Zavarzin, et al.
Positron Emission Mammography: Initial Clinical Results
Ann. Surg. Oncol., January 1, 2003; 10(1): 86 - 91.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. S. Allal, P. Dulguerov, M. Allaoua, C.-A. Haenggeli, E. A. El Ghazi, W. Lehmann, and D. O. Slosman
Standardized Uptake Value of 2-[18F] Fluoro-2-Deoxy-D-Glucose in Predicting Outcome in Head and Neck Carcinomas Treated by Radiotherapy With or Without Chemotherapy
J. Clin. Oncol., March 1, 2002; 20(5): 1398 - 1404.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. Vranjesevic, J. E. Filmont, J. Meta, D. H. Silverman, M. E. Phelps, J. Rao, P. E. Valk, and J. Czernin
Whole-Body 18F-FDG PET and Conventional Imaging for Predicting Outcome in Previously Treated Breast Cancer Patients
J. Nucl. Med., March 1, 2002; 43(3): 325 - 329.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Bos, J. J.M. van der Hoeven, E. van der Wall, P. van der Groep, P. J. van Diest, E. F.I. Comans, U. Joshi, G. L. Semenza, O. S. Hoekstra, A. A. Lammertsma, et al.
Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography
J. Clin. Oncol., January 15, 2002; 20(2): 379 - 387.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. B. Eubank, D. A. Mankoff, J. Takasugi, H. Vesselle, J. F. Eary, T. J. Shanley, J. R. Gralow, A. Charlop, G. K. Ellis, K. L. Lindsley, et al.
18Fluorodeoxyglucose Positron Emission Tomography to Detect Mediastinal or Internal Mammary Metastases in Breast Cancer
J. Clin. Oncol., August 1, 2001; 19(15): 3516 - 3523.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. E. Mortimer, F. Dehdashti, B. A. Siegel, K. Trinkaus, J. A. Katzenellenbogen, and M. J. Welch
Metabolic Flare: Indicator of Hormone Responsiveness in Advanced Breast Cancer
J. Clin. Oncol., June 1, 2001; 19(11): 2797 - 2803.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps
A Tabulated Summary of the FDG PET Literature
J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2000 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online